Clinical Trial Results: Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results for Olvi-Vec oncolytic immunotherapy in recurrent or refractory ovarian cancer show completed study with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Carcinomatosis

Drugs mentioned

• Olvi-Vec

Snippet

Sponsor: Genelux Corporation | Conditions: Ovarian Cancer, Peritoneal Carcinomatosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-06-12